BioHabana 2024.

**Cancer Symposium**

|  |
| --- |
| *Tuesday, April 2nd* |
| 9:00  | 9:10 |  | **Cancer Session Introductory words: Dr. Circe Mesa (Scientific Coordinator Cancer Session)** |
| 9:10 | 9:15 |  | **Introductory words (Chairpersons- Dr. K Lee and Dr. Julio R. Fernández)** |
| 9:15 | 9:55  | KL | How IELSG had changed the treatment of extranodal lymphomas**. Prof. Franco Cavalli.** Institute of Oncology Research. **Switzerland**. |
| 9:55 | 10:10 | SOP | Diffuse Large B-Cell Lymphoma: real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone in Cuba. **Elias Gracia Medina, MD.** Institute of oncology and Radiobiology. **Cuba** |
| 10:10  | 10:40 | OL | B Lymphocytes Produce Extracellular Vesicles of Two Sizes that Contain Antibody and Can Deposit Their Contents Inside Target Cells. **Thomas L. Rothstein, MD, PhD.** Western Michigan University Homer Stryker MD School of Medicine, **USA**. |
| 10:40 | 11:10 | OL | Superhigh-Capacity Polymeric Micelles for Chemo/Immunotherapy of Cancer **Alexander Kabanov, Ph.D., Dr.Sci.** UNC-Chapel Hill. **USA** |
| *11:10*  | *11:30*  |  | *Coffee Break* |
| 11:30 | 12:00  | OL | Intravital imaging technology to study cancer dissemination in the lymphatic compartment. **Santiago F. González. PhD.** Institute for Research in Biomedicine. **Switzerland** |
| 12:00 | 12:30 | OL | Pros and cons of senescence in cancer. **Prof. Andrea Alimonti, PhD**. Institute of Oncology Research. **Switzerland** |
| 12:30 | 1:00:00  | OL | “Reprograming the suppressive myeloid cells in cancer using a proteolipidic nanoparticle”. **Circe Mesa Pardillo, PhD**. Center for Molecular Immunology & Innovative Immunotherapy Alliance. **Cuba** |
| 1:00:00  | 1:30:00  | OL | CIGB-552: Target Therapy for Cancer through COMMD1 stabilization. **Julio Raúl Fernández Masso, PhD.** Center for Genetic Engineering and Biotechnology. **Cuba** |
| 1:30:00  | 2:00:00  | OL | PIM2 kinase independent function supports multiple myeloma survival. **Kelvin P. Lee.** IU Simon Comprehensive Cancer Center & Indiana University School of Medicine. **USA** |

|  |
| --- |
| *Wednesday, April 3rd* |
| 9:00  | 9:10 |  | **Introductory words (Chairpersons- Dr. Mary Reid and Dr. Tania Crombet)** |
| 9:10 | 9:40  | OL | Overview of current agents in study for Lung Cancer prevention (**Definitive Title to be defined**). **Mary Reid, PhD.** Roswell Park Comprehensive Cancer Center. **USA** |
| 9:40  | 10:10 | OL | Clinical relevance of liquid biopsy in patients with lung cancer treated with immunotherapy. **Patrizia Froesch, MD, PhD.** Istituto Oncologico della Svizzera Italiana. **Switzerland** |
| 10:10 | 10:40 | OL | CIMAvax-EGF: An EGF depleting immunotherapy for advanced non-small cell lung cancer. **Tania Crombet, MD, PhD**. Center for Molecular Immunology. **Cuba** |
| 10:40 | 10:55  | SOP | Clinical relevance of KRAS-TP53 co-mutations in lung adenocarcinoma patients. **Patrizia Froesch, MD, PhD.** Istituto Oncologico della Svizzera Italiana. **Switzerland** |
| 10:55 | 11:10 | SOP | CD36 expression modulates the tumor immune microenvironment in mouse melanoma. **Nely Rodriguez Zhurbenko, PhD.** Center for Molecular Immunology. **Cuba** |
| *11:10*  | *11:30*  |  | *Coffee Break* |
| 11:30 | 12:00  | OL | CIGB-300: Towards a Rational Approach to Treat Cervical Cancer and Other Genital Lesions. **Silvio E. Perea, PhD.** Center for Genetic Engineering and Biotechnology. **Cuba** |
| 12:00 | 12:30 | OL | Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba. **Elias Gracia Medina, MD.** Institute of oncology and Radiobiology. **Cuba** |
| 12:30 | 1:00  | OL | PET/CT with new PET tracers in nuclear medicine in the Russian Federation. **A.I. Pronin, MD.** National Medical Research Center of Oncology named after. N.N. Blokhin. **Russia**. |
| 1:00  | 1:30 | OL | Itolizumab as a potential anti-checkpoint inhibitor for the treatment of cancer patients. **Cynthia González Muñoz, MSc** Center for Molecular Immunology. **Cuba** |
| 1:30  | 1:45  | SOP | Preclinical studies of a novel human PD-L1 based- cancer vaccine: from mice to non-human primates experiments. **Yanelys Morera Diaz, PhD.** Center for Genetic Engineering and Biotechnology. **Cuba** |
| 1:45 | 2:00 | SOP | Targeting CK2-mediating signaling in NSCLC: A synthetic Cell Penetrating Peptide-based approach. **Yasser Perera Negrin, PhD.** Cuba China Biotechnology Joint Innovation Center. **China** |

|  |
| --- |
| *Thursday, April 4th* |
| 9:00  | 9:05 |  | **Introductory words (Chairpersons- Dr. Anupam Bishayee and Dr. Yanelys Morera Diaz)** |
| 9:05 | 9:45 | KL | The Microbiome: An Emerging Orchestrator in Cancer Pathogenesis and Therapeutics. **Prof. Raúl de Jesús Cano Chauvell. PhD.** EDC BioSynergy, **USA*****Note****: For this conference, the Microbiome mini-symposium and the Cancer session will meet together. (Plenary Room)* |
| 9:45 | 10:25  | KL | Biotechnology in the discovery and development of anticancer phytocompounds: Advances, challenges and opportunities. **Anupam Bishayee, PhD.** Lake Erie College of Osteopathic Medicine, **USA** |
| 10:25 | 10:55 | OL | VEGF deprivation using an active immunotherapeutic approach in solid tumors: insights from HEBERSaVax preclinical and clinical studies. **c, PhD** Center for Genetic Engineering and Biotechnology. **Cuba** |
| 10:55 | 11:25  | OL | HeberFERON in brain tumors. **Iraldo Jesus Bello Rivero, PhD.** Center for Genetic Engineering and Biotechnology. **Cuba** |
| *11:25*  | *11:45* |  | *Coffee Break* |
|  |  |  | **Chairpersons- Dr. Marco Davila and Dr. Kalet Leon** |
| 11:45 | 12:15 | OL | No alpha mutein of Interleukin 2 for the stimulation of effector cells through βγ IL-2 receptor: a winning strategy for antitumor therapy. **Kalet Leon Monzon, PhD.** Center for Molecular Immunology. **Cuba** |
| 12:15 | 12:30 | SOP | Stimulation of effector cells through βγ IL-2 receptor for antitumor therapy. **Ernesto Relova, BSc.** Center for Molecular Immunology. **Cuba** |
| 12:30 | 1:00 | OL | ABCB5-targeted antibody-drug-conjugates for cancer immunotherapy. **Markus H. Frank, MD.** Boston Children’s Hospital. **USA** |
| 1:00 | 1:15 | SOP | The anti-CD20(hγ1)-IL2no-alpha immunocytokine: a promise for the therapy of Non-Hodgkin B cell Lymphoma. **Ana Victoria Casadesus Pasos, PhD.** Center for Molecular Immunology. **Cuba** |
| 1:15 | 1:45  | OL | CAR T cells for hematologic malignancies. **Marco Davila, MD, PhD.** Roswell Park Comprehensive Cancer Center. **USA** |
| 1:45 | 2:00 | SOP | T cell recruiting anti-NGcGM3 antibodies: novel strategy in cancer immunotherapy. **Claudia Placencia, MSc.** Center for Molecular Immunology. **Cuba** |

|  |
| --- |
| *Friday, April 5th* |
| 9:00  | 9:05 |  | **Chairpersons- Dr. Belinda Sanchez and Dr.** **Andrei Gudkov** |
| 9:05 | 9:35  | OL | Aging, entropy and limits of age reversal. **Peter Fedishev, PhD**. Gero.ai, **Singapore** |
| 9:35  | 10:05  | OL | The role of endogenous ‘retrobiome’ control in tumor suppressor function of p53. **Andrei Gudkov, PhD.** Roswell Park Comprehensive Cancer Center. **USA** |
| 10:05 | 10:35 | OL | Multivalent vaccines specific for HER/ErbB receptors as a therapeutic alternative for cancer treatment: preclinical and clinical evidences. **Belinda Sanchez Ramirez, PhD.** Center for Molecular Immunology. **Cuba** |
| 10:35 | 11:05  | OL | Nimotuzumab in the treatment of tumors of epithelial origin: new pieces of information in head and neck and pancreatic tumors. **Mayra Ramos Suzarte, PhD.** Center for Molecular Immunology. **Cuba** |
| *11:10*  | *11:30*  |  | *Coffee Break* |
| 11:30 | 12:00  | OL | Targeting EGFR inhibitor resistance in colorectal cancer. **Natasha Y Frank, M.D.** Brigham and Women’s Hospital, **USA.** |
| 12:00 | 12:30 | OL | Innovative technologies in the treatment of oncological diseases in the Russian Federation. **Andrey Dmitrievich Kaprin, MD, PhD.** National Center for Medical Research in Radiology and Oncology. **Russia** |